Cutting-edge AI Models 1910 Genetics is leading the market with advanced AI models for drug discovery and blood-brain barrier permeability prediction, providing a unique selling point for pharmaceutical partners looking to innovate in drug development.

Top Talent Acquisition With recent key hires to their C-suite and board of directors, such as the appointment of a new Chief Scientific Officer and independent board director, 1910 Genetics showcases a strong leadership team that enhances credibility and expertise, potentially attracting pharma partners in need of reliable and visionary leadership.

Strategic Funding Having secured investments from reputable sources like M12 - Microsoft's Venture Fund and the National Institutes of Health, 1910 Genetics demonstrates financial stability and industry recognition that can be leveraged as a selling point to potential customers seeking partnerships with established and well-supported biotech companies.

Innovative Technology Stack Utilizing a tech stack that includes Google Analytics, NoSQL, Python, and Node.js, 1910 Genetics showcases a commitment to cutting-edge technologies that can appeal to tech-savvy pharmaceutical companies looking to collaborate with partners at the forefront of innovation in biotechnology research.

Market Recognition and Positioning Being recognized for their novel approach to drug discovery and having received significant funding, 1910 Genetics has established a strong foothold in the biotechnology research industry. Leveraging this recognition and market positioning, the company can effectively pitch their services to potential partners looking for industry disruptors.